Simulations Plus, Inc.
SLPHealthcareNASDAQHealth Information Services
Scan Results
Daily timeframeSimulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company carries a $345.7M market cap, placing it firmly in the small-cap category. It operates through Software and Services segments.
Market Cap
$345.7M
Beta
1.28
P/E (TTM)
—
P/E (Fwd)
18.56
EPS (TTM)
$-3.12
EPS (Fwd)
$0.92
ROE
-38.8%
ROA
3.8%
Cash
$41.8M
Total Debt
$508,000
Free CF
$17.2M
52W Change
-35.1%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $41.8M in cash comfortably exceeding the $508K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company generates $17.2M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at -38.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 3.8% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $53.9M (2022) to $79.2M (2025), reflecting a 47% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. No single metric tells the full story. Reviewing SLP's risk profile alongside its fundamentals and technical indicators provides a more complete picture.